In a significant move for pharmaceutical transparency, the Bristol Myers Squibb-Pfizer Alliance announced that Eliquis® (apixaban), one of the world’s most widely prescribed blood thinners, will soon be available through Mark Cuban’s direct-to-consumer pharmacy.
Ponce Financial Group (NASDAQ:PDLB) reported a profitable start to 2026, characterized by a double-digit rise in shareholder equity and a stable interest margin that underscores the lender’s successful navigation of the current rate environment.
The Western Union Company (NYSE:WU) reported mixed first-quarter results as the legacy remittance giant works to offset retail headwinds in the Americas through an aggressive digital expansion and a foray into blockchain-native payment systems.
ChoiceOne Financial Services NASDAQ:COFS) reported a strong start to 2026, driven by a significant expansion in its net interest margin and robust organic deposit growth that fortified the community bank’s balance sheet.
WiMi Hologram Cloud (NASDAQ:WIMI) reported a massive surge in annual profitability for 2025, underscoring a successful transition toward leaner operations and a significantly fortified balance sheet.
HCA Healthcare (NYSE:HCA) posted a solid start to 2026, delivering a double-digit increase in earnings per share as steady patient volumes and operational "resiliency" initiatives helped the hospital giant navigate a complex reimbursement landscape.
Charter Communications (NASDAQ:CHTR) reported a slight dip in first-quarter revenue and earnings, as record-breaking growth in its mobile segment struggled to fully compensate for a cooling residential broadband market.
The Procter & Gamble Company (NYSE:PG) reported a robust rise in third-quarter sales and earnings, underpinned by steady consumer demand and a strategic portfolio adjustment that provided a significant boost to the bottom line.
SLB reported a slight increase in first-quarter revenue, but the world’s largest oilfield services provider saw its earnings retreat as production disruptions in the Middle East pressured operational margins and dampened bottom-line performance.
Merck (NYSE:MRK) has moved a step closer to finalizing its multi-billion dollar bet on the next generation of blood cancer treatments, clearing a key federal antitrust review for its acquisition of Terns Pharmaceuticals.
Rithm Property Trust reported a net loss for the first quarter of 2026 as market-driven adjustments weighed on comprehensive income, though the real estate investment platform maintained its quarterly dividend distribution.
Arrowhead Pharmaceuticals is on the verge of its first European commercial launch after regulatory advisors recommended the approval of its siRNA therapy, REDEMPLO, for a rare and potentially life-threatening lipid disorder.
